Pfizer Inc (PFE)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	2,119,000	10,482,000	21,472,000	29,051,000	31,372,000	29,771,000	29,309,000	24,966,000	21,979,000	19,432,000	12,755,000	10,681,000	9,159,000	7,730,000	13,941,000	15,498,000	16,027,000	16,217,000	12,651,000	11,477,000
Total assets	US$ in thousands	227,000,000	215,021,000	220,000,000	195,617,000	197,000,000	195,350,000	195,290,000	183,841,000	181,000,000	179,188,000	169,920,000	158,818,000	154,229,000	178,983,000	178,000,000	166,000,000	167,594,000	170,000,000	156,000,000	155,421,000
ROA		0.93%	4.87%	9.76%	14.85%	15.92%	15.24%	15.01%	13.58%	12.14%	10.84%	7.51%	6.73%	5.94%	4.32%	7.83%	9.34%	9.56%	9.54%	8.11%	7.38%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $2,119,000K ÷ $227,000,000K
= 0.93%

Pfizer Inc.'s return on assets (ROA) has shown variability over the eight quarters provided. The ROA trend indicates a decline from 15.91% in Q4 2022 to 0.94% in Q4 2023. This drop could be a cause for concern as it signifies a substantial decrease in the company's ability to generate profits from its assets.

However, it is important to note that the Q4 2023 ROA figure may be an outlier or influenced by temporary factors. Quarter-to-quarter fluctuations in ROA are not uncommon and can be due to various factors such as changes in asset allocation, acquisitions, or economic conditions.

Overall, Pfizer Inc. has historically maintained a relatively strong ROA, demonstrating its efficiency in utilizing its assets to generate profits. Investors and stakeholders should continue to monitor the company's ROA trend over time to assess its operational performance and financial health accurately.